AI주식인사이트AI Stock Insight
C

뷰노

338220KOSDAQ소프트웨어 개발 및 공급업

42.5 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 8.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

VUNO is a pioneer in medical IT, leveraging deep learning to provide innovative solutions such as cardiac arrest prediction, fundus image analysis, and chest X-ray diagnostics. Its key product, VUNO Med-DeepCARS, received FDA Breakthrough Device Designation in 2023 and is actively expanding into the U.S. market. The company is transitioning to a SaaS-based subscription model, with the prognosis and prediction solutions driving the majority of its revenue.

Number of Employees

165people

Average Salary

80.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 14.434.0Point
PBR
6.43Industry Average 1.280.0Point

5.0x industry avg (risky)

ROE
-17.30Industry Average 1.360.0Point

Well below industry avg

Debt Ratio
5.13Industry Average 7.935.0Point

Lower than industry avg (good)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲64.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲40.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -74.0% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 16,590Won52-week high 27,60052-week low 14,800
1-month return1.0Point

1m -8.34% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral[기재정정]정기주주총회결과2026-04-01
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
  • Neutral감사보고서제출2026-03-18
  • Neutral사업보고서 (2025.12)2026-03-18